New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareNAD+ vs Ovagen

NAD+ vs Ovagen

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
NAD+
Anti-Aging & Longevity
Ovagen
Summary
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells that declines dramatically with age. It is critical for energy metabolism, DNA repair, and sirtuin activation. IV and subcutaneous NAD+ supplementation is used in anti-aging protocols and addiction recovery programs.
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Half-Life
Varies by route; IV provides direct cellular delivery
Short (minutes); sustained gene-regulatory effects
Admin Route
IV, SubQ, Oral
SubQ, Oral
Research
Typical Dose
500–1000 mg
10 mg per day
Frequency
Daily for 4–10 days (loading), then monthly maintenance
Daily for 10–30 days
Key Benefits
  • Restored cellular energy production (ATP)
  • Sirtuin activation for longevity and metabolic regulation
  • Enhanced DNA repair capacity
  • Improved mitochondrial function and biogenesis
  • Cognitive clarity and mental energy
  • Reduced inflammation
  • Addiction withdrawal support (opioids, alcohol, benzodiazepines)
  • Improved sleep quality
  • Enhanced athletic endurance
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
Side Effects
  • Flushing and warmth during IV infusion
  • Nausea during rapid IV administration
  • Chest tightness (from rapid infusion — slow the rate)
  • Injection site irritation (subcutaneous)
  • +1 more
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
Stacks With